Precision therapies reshape neurology, immunology markets

Monoclonal antibodies are the most impactful modality.

Immunology and neurology therapeutics are currently undergoing a market shift as stakeholders prefer precision-targeted modalities.

According to GlobalData, in neurology, precision biologics, gene therapies, and psychedelic-assisted modalities are converging toward a mid-term approval wave.

The report noted that monoclonal antibodies (mAbs) are the most impactful modality, with 41% of pharmaceutical professionals expecting them to have the greatest impact over the next one to three years.

This was closely followed by 37% of respondents identifying bispecific/trispecific antibodies and 36% saying Treg cells and T cell engagers as those with the most potential.

In the neurology space, small-molecule (50%) and gene therapy approaches (44%) are still dominant, identifying these as the modalities expected to have the most impact.

However, they are facing competition from mAbs and targeted protein degraders in neurology, which ranked jointly in third place.

Moreover, bi or multispecific antibodies are currently critical for research and development across immunology indications of potentially safer and more effective targeted treatment options.

In neurology, spinal muscular atrophy (SMA) leads the gene therapy pipeline with 12 programmes and is the only indication with a marketed asset.